(Zhang Xun, president of Boston Science Greater China, Photo Source: photo provided by interviewees)

Economic observation Network Shen Jianyuan / articleOn November 10th, the fourth China International Import Expo (hereinafter referred to as "Jin Expo") came to a successful conclusion. Boston Science announced that Axios, the world's first endoscopic ultrasound-guided intracavitary stent, has been launched in China. After the product was unveiled in the new product release platform of the Expo last year, it has received wide attention from the industry, and has been officially approved by the State Drug Administration to be listed on the market, becoming the first official landing of Boston Science.

Zhang Xun, president of Boston Science Greater China, said that thanks to the spillover effects of previous fairs, a number of exhibits that had been unveiled in the exhibition in 2019 are accelerating the transformation of "exhibits into commodities".

As the world's leading medical technology company, Boston Science demonstrated its innovative solutions in the field of minimally invasive intervention at the 4th Expo. Including more than 60 innovative solutions covering vascular health, atrial fibrillation treatment and stroke prevention, heart failure management and sudden death prevention, urinary and pelvic floor health, disposable endoscopy, and tumor intervention, nearly half of them are not yet on the market in China. including a number of "global first" and "Asia first" solutions, and released four innovative products.

At the same time, Boston Science focused on promoting another "Jin Bo with the same money"-Rez thermotherapy ablation system, the world's first steam thermotherapy ablation system for the treatment of benign prostatic hyperplasia, which was unveiled at the Expo for the first time in November last year. At the same time, with the help of the policy of Hainan Free Trade Port, it successfully entered the "early and pilot" channel of the Boao Le City advance area. at present, it has treated nearly 60 patients and is expected to officially land in the Chinese market in the coming year. Accelerate the benefit of Chinese patients.

As one of the medical device companies with the largest R & D investment in the world, a number of Galen Award-winning or nominated products of Boston Science and Technology, as well as innovative solutions in six major areas, have received extensive attention at this Expo. In addition, Boston Science focused on patients with atrial fibrillation, highlighting two cutting-edge medical products: FARAPULSE, the world's only listed pulsed electric field ablation system, made its "Asian premiere" on the Beau stage; and following the "Galen Award" award-winning WATCHMAN ®left atrial appendage occluder, WATCHMAN ®FLX, Boston Science's landmark left atrial appendage occluder device, was pre-launched to jointly optimize current atrial fibrillation treatment and stroke prevention strategies.

Zhang Xun, president of Boston Science Greater China, said, "Boston Science will continue to take root in the local ecosystem with the core strategic objectives of 'increasing market coverage', 'accelerating innovation transformation' and 'expanding internal and external cooperation'. Help China lead medical innovation."

As a member of the Secretariat of the Medical Devices Special Committee of the Expo, during the exhibition, Boston Science also reached more than 10 cooperation intention agreements with local partners in various fields to further expand the accessibility of innovative medical products.